ArticleEmerging infectious diseases2019
Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi Arabia.
Article in Emerging infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.Nature communications · 2020Pooled it
- Changes in Glycemic Control and Lipid Profiles Following COVID-19 Infection in Adults with Type 2 Diabetes: A Retrospective Study in Saudi Arabia.Pathogens (Basel, Switzerland) · 2026Article
- Detectability of Pathogenic RNA Virus Families in Different Body Sites: A Scoping Review.Viruses · 2026Article
- Ordinary differential equation models of SARS-CoV-2 replication dynamics and antiviral drug efficacies.Npj viruses · 2026Review
- Article
- Molecular Diagnosis of COVID-19; Biosafety and Pre-analytical Recommendations.Iranian journal of pathology · 2023Review
- Time Course Evaluation of Enzyme-Linked Immunosorbent Assays Based on Cell-Free Recombinant Proteins for Detection of Antibodies against Middle East Respiratory Syndrome Coronavirus.Microbiology spectrum · 2022Article
- Neuraminidase inhibitor treatment is associated with decreased mortality in COVID-19 patients: a retrospective analysis.European heart journal. Cardiovascular pharmacotherapy · 2022Article
- Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.Cell reports. Medicine · 2022Article
- Landscapes and dynamic diversifications of B-cell receptor repertoires in COVID-19 patients.Human immunology · 2022Article
- 'Convalescent Plasma'- An Effective Treatment Option to Prevent Emerging nCOVID-19- A Review.Infectious disorders drug targets · 2022Article
- SARS-CoV-2 Viral Shedding and Associated Factors among COVID-19 Inpatients and Outpatients.Interdisciplinary perspectives on infectious diseases · 2022Article
- Molecular Modeling and Simulation Analysis of Antimicrobial Photodynamic Therapy Potential for Control of COVID-19.TheScientificWorldJournal · 2022Article
- Kinetics of antibody response in critically ill patients with Middle East respiratory syndrome and association with mortality and viral clearance.Scientific reports · 2021Article
- Development of an Enzyme-Linked Immunosorbent Assay (ELISA) for Accurate and Prompt Coronavirus Disease 2019 (COVID-19) Diagnosis Using the Rational Selection of Serological Biomarkers.Diagnostics (Basel, Switzerland) · 2021Article
- Elevated Expression Levels of Lung Complement Anaphylatoxin, Neutrophil Chemoattractant Chemokine IL-8, and RANTES in MERS-CoV-Infected Patients: Predictive Biomarkers for Disease Severity and Mortality.Journal of clinical immunology · 2021Article
- Humoral immune mechanisms involved in protective and pathological immunity during COVID-19.Human immunology · 2021Review
- An Overview of the Pathogenesis, Transmission, Diagnosis, and Management of Endemic Human Coronaviruses: A Reflection on the Past and Present Episodes and Possible Future Outbreaks.Pathogens (Basel, Switzerland) · 2021Review
- Personal protective equipment in the siege of respiratory viral pandemics: strides made and next steps.Expert review of respiratory medicine · 2021Review
- Myocardial Injury on Admission as a Risk in Critically Ill COVID-19 Patients: A Retrospective in-ICU Study.Journal of cardiothoracic and vascular anesthesia · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) shedding and antibody responses are not fully understood, particularly in relation to underlying medical conditions, clinical manifestations, and mortality. We enrolled MERS-CoV-positive patients at a hospital in Saudi Arabia and periodically collected specimens from multiple sites for real-time reverse transcription PCR and serologic testing. We conducted interviews and chart abstractions to collect clinical, epidemiologic, and laboratory information. We found that diabetes mellitus among survivors was associated with prolonged MERS-CoV RNA detection in the respiratory tract. Among case-patients who died, development of robust neutralizing serum antibody responses during the second and third week of illness was not sufficient for patient recovery or virus clearance. Fever and cough among mildly ill patients typically aligned with RNA detection in the upper respiratory tract; RNA levels peaked during the first week of illness. These findings should be considered in the development of infection control policies, vaccines, and antibody therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.